3 results
Approved WMOCompleted
To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.
Approved WMOCompleted
What is the correlation between change in % fall in FEV1 (*FEV1) after an exercise challenge 20h after a single dose of montelukast and after 4 weeks of treatment with montelukast?
Approved WMOCompleted
To evaluate the safety and efficacy of PRX-102 in patients with Fabry disease currently treated with agalsidase alfa